Krystal Biotech
KRYS
188 hedge funds and large institutions have $2.76B invested in Krystal Biotech in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 89 increasing their positions, 52 reducing their positions, and 14 closing their positions.
71% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 52
50% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 14
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
3% more funds holding
Funds holding: 183 → 188 (+5)
2% more capital invested
Capital invested by funds: $2.71B → $2.76B (+$54.6M)
4.34% less ownership
Funds ownership: 89.36% → 85.02% (-4.3%)
42% less call options, than puts
Call options by funds: $22.5M | Put options by funds: $38.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84.7M |
| 2 |
Jennison Associates
New York
|
+$34.5M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$33.9M |
| 4 |
FAM
Fred Alger Management
New York
|
+$20M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$68.7M |
| 2 |
AG
Artal Group
Luxembourg
|
-$41.1M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$28.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$20.9M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$20M |
KRYS Hedge Fund Activity: Q3 2023 in Review
188 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2023, worth a combined $2.76B — up 2% from $2.71B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new KRYS positions and 14 closed out — a net gain of 7 holders — while 89 added to existing stakes and 52 trimmed.
The largest buyer was Vanguard Group, adding an estimated $84.7M. The largest seller was Redmile Group, cutting an estimated $68.7M.
- 188 institutional investors held Krystal Biotech (KRYS) as of Q3 2023, up from 183 in Q2 2023.
- Funds reported $2.76B of Krystal Biotech stock for Q3 2023, up 2% quarter-over-quarter.
- 21 funds opened new Krystal Biotech positions in Q3 2023 and 14 closed out, a net change of +7 holders.
- The largest Krystal Biotech buyer in Q3 2023 was Vanguard Group, an estimated $84.7M added.
- The largest Krystal Biotech seller in Q3 2023 was Redmile Group, an estimated $68.7M sold.
Based on aggregated 13F filings for Q3 2023.